- Home
- PLUG vs ATAI Comparison
PLUG vs ATAI Comparison
Compare PLUG & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUG | ATAI |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 1999 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PLUG | ATAI |
|---|---|---|
| Price | $2.29 | $7.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $2.31 | ★ $15.88 |
| AVG Volume (30 Days) | ★ 57.5M | 8.6M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,919,000.00 | $4,089,000.00 |
| Revenue This Year | $26.67 | N/A |
| Revenue Next Year | $8.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 12.90 | ★ 1227.60 |
| 52 Week Low | $1.41 | $3.27 |
| 52 Week High | $4.58 | $7.45 |
Technical Indicators
Market Signals| Indicator | PLUG | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 75.74 |
| Support Level | $2.11 | $3.89 |
| Resistance Level | $2.50 | N/A |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 54.37 | 87.93 |
Price Performance
Historical ComparisonAbout PLUG Plug Power Inc.
Plug Power Inc is building an end-to-end green hydrogen ecosystem, from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.